Pfizer CEO expects COVID vaccine trials for kids to be completed in September

·1 min read
A coronavirus vaccine vial.
A coronavirus vaccine vial. Sean Rayford/Getty Images

The Pfizer-BioNTech COVID-19 vaccine was fully approved on Monday by the Food and Drug Administration for people 16 and older, but it will still be some time before it's authorized for use in young children.

The Pfizer vaccine is available for kids between the ages of 12 and 15 under an emergency use authorization. Before emergency use authorization can be expanded to kids under 12 — which is expected this fall or winter, NBC News reports — clinical trials must be completed. Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, told reporters on Monday the agency needs to have a "good safety dataset, because we certainly want to make sure we get it right in the children ages 5 through 11 and then even in younger children after that."

Pfizer and Moderna are both conducting vaccine trials in kids to determine the proper dosage and whether it is safe and effective for younger people. Pfizer CEO Albert Bourla told NBC News on Monday he expects studies on children ages 5 to 11 will finish in September, and the data will then get submitted to the FDA. Following adult vaccine trials, the FDA asks for two months worth of follow-up safety data, but for the children's trials, the FDA is requesting four to six months of data.

In the week ending last Thursday, there were 180,000 new cases of COVID-19 among kids and teenagers, the American Academy of Pediatrics said in a statement on Monday, and the organization is urging the FDA to "work aggressively to authorize a vaccine for ages 11 and younger."

You may also like

Actor suspected of participating in Capitol attack arrested in California

10 things you need to know today: August 22, 2021

Xi seeks submission from business giants

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting